Vistagen in freefall as social anxiety drug fails Phase 3
Phase 3negativeNegative
AI Analysis
Summary
Vistagen's Phase 3 trial for a social anxiety drug candidate failed. The company plans to continue development and meet with the FDA to determine a potential registrational pathway.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failed for social anxiety drug candidate
Importance:8/10
Sentiment:
-0.85
Phase 3 failuresocial anxietyclinical triallate-stage development
Related Companies
Read the original article
Published by BioSpace on July 1, 2026 12:13 PM